港產半導體「無冕獨角獸」走出困局扭虧為盈 晶門王華志:香港要凝聚創新氛圍

// “For example, a few years ago, we acquired Microchip Technology and gained a team in the UK. We then started developing touch technology, which is now used in the touchpad of the PS5 controller. Many PS5 players may not realize that the touch technology in the PS5 controller is actually developed and owned by a Hong Kong semiconductor company.”

「再​​舉例來說,幾年前我們收購了 Microchip Technology,獲得了一支英國的團隊,我們隨後開始研發觸控技術,如今這部分的業務,就應用於 PS5 的遊戲手掣觸控版。很多 PS5 玩家可能想不到,PS5 遊戲手掣觸控技術,其實是由一家香港半導體公司開發和擁有。」 https://unwire.pro/2023/05/19/hk-semiconductor-unicorn-solomon-systech/feature/ //

Hong Kong’s e-HKD Pilot Program to Pave the Way for Retail … – BSC NEWS

// Tron 創辦人孫宇晨表示支持e-HKD試點計劃,並強調火幣全球對央行數字貨幣(CBDC)的支持。香港金融管理局(HKMA)宣布了e-HKD試點計劃的啟動,涉及金融、支付和科技等行業的16家選定公司。

Tron founder Justin Sun has expressed his support for the e-HKD Pilot Program, highlighting Huobi Global’s willingness to back central bank digital currencies (CBDCs). The Hong Kong Monetary Authority (HKMA) has announced the start of the e-HKD Pilot Programme, involving 16 selected firms from the financial, payment, and technology sectors. https://www.bsc.news/post/hong-kongs-e-hkd-pilot-program-to-pave-the-way-for-retail-cbdcs-justin-sun //

Hong Kong-Based Hashkey’s Billion-Dollar Dream: The Next Big Bang In Crypto

// 據彭博社報導,Hashkey 正考慮籌集 1 億至 2 億美元的資金。然而,交易的詳細細節,例如確切金額和估值,仍然有待確定,因為尚未敲定。

Quoting sources, Bloomberg reported that Hashkey is considering raising between $100 million and $200 million. However, details of the transaction, such as the exact figure and valuation, are still subject to change as they are not yet cemented. https://www.benzinga.com/markets/cryptocurrency/23/05/32482250/hong-kong-based-hashkeys-billion-dollar-dream-the-next-big-bang-in-crypto //

Digital Hong Kong Dollar Trial Underscores Web3 Hub Ambitions – Blockworks

// 被稱為e-HKD或「數碼港元」,其試驗運行是邁向金融交易數字化的又一步,該監管機構兼任該地區的「中央銀行」金管局在聲明中表示。該測試運行在受控的沙盒環境中進行,旨在探索多種應用,包括在線和離線支付、代幣化存款、可編程支付、Web3交易結算以及代幣化資產結算等。

Dubbed the e-HKD or “Cyber Hong Kong Dollar,” its trial run marks another step towards digitizing financial transactions, the regulator, who also doubles as the region’s central bank, said in a statement. The test run, operating within a controlled sandbox environment, is designed to explore multiple applications ranging from online and offline payments, tokenized deposits, programmable payments and Web3 transaction settlement to tokenized asset settlement https://blockworks.co/news/digital-hong-kong-dollar-trial //

China state-owned Greenland to apply for Hong Kong virtual asset trading license

// 據《南華早報》報導,綠地控股的一家子公司正在香港申請虛擬資產交易許可證。如果成功,這將成為首家中國國有企業獲得這種許可證。

A Greenland Holdings subsidiary is applying for a virtual asset trading license in Hong Kong, the South China Morning Post reported. It is the first state-owned Chinese company to do so. https://coinspectator.com/cointelegraph/2023/05/17/china-state-owned-greenland-to-apply-for-hong-kong-virtual-asset-trading-license/ //

Qiming Venture Partners closes its seventh RMB fund, raising US$940.4 million

// 啓明創投於週四宣布,已完成第七個人民幣基金的籌款,金額為65億人民幣(9.404億美元),這是中國風險投資市場今年目前最大的人民幣籌款。這次的籌款使得啓明共籌得95億美元的資本,涵蓋18個基金,專注於科技、消費品和醫療保健行業的早期和成長階段企業的投資。

Qiming Venture Partners announced on Thursday that it had closed its seventh renminbi fund at 6.5 billion yuan ($940.4 million), which it claims is the largest renminbi fundraising in China’s venture capital market this year. This latest close brings Qiming’s total capital raised to $9.5 billion across 18 funds, which focus on investments in early and growth-stage firms in the technology, consumer, and healthcare sectors. https://www.dimsumdaily.hk/qiming-venture-partners-closes-its-seventh-rmb-fund-raising-us940-4-million/ //

Reforgene Biotech Completes $15 Million Pre-B Round for Gene Editing Drugs

// 廣州銳合基因科技完成了一筆1500萬美元的B輪融資,用於其基因編輯候選藥物組合的研發,包括一種針對地中海貧血的臨床階段治療方案。 在一項I期臨床試驗中,該公司的首個β地中海貧血基因編輯藥物RM-001取得了100%的治癒率。 此外,銳合還在眼科、神經系統和其他領域開發體內基因編輯療法,用於治療重要的遺傳性疾病。

Guangzhou Reforgene Biotechnology closed a $15 million Pre-B financing for its portfolio of gene editing candidates, including a clinical stage therapy for thalassemia. In a Phase I trial, the company’s lead β-thalassemia gene-editing drug, RM-001, produced a 100% cure rate. In addition, Reforgene is developing in vivo gene editing therapies for major genetic diseases in the fields of ophthalmology, nervous system and other fields. https://chinabio.ssl.subhub.com/articles/reforgene-15-million //

Hong Kong OSL Asset Management secures license to offer AI … – CoinGeek

// 總部位於香港的OSL資產管理有限公司(OSLASM)宣布獲得首席證券監管機構的牌照,授權其涉足區塊鏈技術和人工智能(AI)領域。

Hong Kong-based OSL Asset Management Limited (OSLASM) has announced the receipt of a license from the chief securities regulator authorizing it to dabble in blockchain technology and artificial intelligence (AI). https://coingeek.com/hong-kong-osl-asset-management-secures-license-to-offer-ai-web3-and-blockchain-investments/ //

Proudly powered by WordPress | Theme: Baskerville 2 by Anders Noren.

Up ↑